The aims of this review are to discuss the molecular alterations related to oxidative stress, inflammation, and protein kinase activation that occur under hypobaric hypoxia-induced pulmonary hypertension, particularly in PASMCs, and to identify current and potential molecular targeted pharmacological treatments. This evidence concerns the gene WEE1 and pulmonary hypertension.